Homepage Top Section2

The alliance leverages both companies’ experience in the field of biosimilars. By combining their resources, they aim to expedite the development process while expanding the product’s availability worldwide.

The designation is granted to iopofosine I 131 for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM), a subtype of lymphoplasmacytic lymphoma currently without a cure. WM remains

Lilly will get exclusive, global rights to research, develop, manufacture and commercialise these therapies with Camurus’ FluidCrystal technology. The agreement includes up to four drug compounds from Lilly.

Glepaglutide is intended for administering two times a week for SBS. The application is based on results from the pivotal Phase III clinical trial EASE-1, supported by interim

The company’s wholly owned subsidiary T-mab developed the drug. It is Mabwell’s first commercialised innovative drug, and the first introduced granulocyte colony-stimulating factor (G-CSF) developed with albumin long-acting

Previously known as AR-15512, Tryptyr is a transient receptor potential melastatin 8 (TRPM8) receptor agonist that stimulates corneal sensory nerves to increase production of natural tears rapidly. It

This partnership will advance the receptor-based targeting molecule into clinical development. Under the agreement terms, Archeus Technologies will be responsible for leading the Phase I clinical development of

Radiprodil is being investigated for its potential in treating rare genetic epilepsies and neurodevelopmental disorders (NDDs). It is a targeted, selective and negative allosteric modulator of the GluN2B

HLX22 is the first anti-HER2 targeted treatment to receive ODD from both the US Food and Drug Administration (FDA) in March 2025 and from the EU. An international